Literature DB >> 35527985

Metabolic Regulation of Fibroblast Activation and Proliferation during Organ Fibrosis.

Sudan Wang1, Yan Liang1, Chunsun Dai1,2.   

Abstract

Background: Activated fibroblasts are present in the injury response, tumorigenesis, fibrosis, and inflammation in a variety of tissues and myriad disease types. Summary: During normal tissue repair, quiescent fibroblasts transform into a proliferative and contractile phenotype termed myofibroblasts and are then lost as repair resolves to form a scar. When excessive levels are reached, activated fibroblasts proliferate and produce large amounts of extracellular matrix, which accumulates in the interstitial space of different organs. This accumulation leads to fibrotic dysfunction and multiple-organ dysfunction syndrome. To date, there are limited effective treatments for these conditions. Cellular metabolism is the cornerstone of all biological activities. Emerging evidence shows that metabolic alterations in fibroblasts are important for the activation process and illness progression. These discoveries, along with current clinical advances showing decreased lung fibrosis after targeting specific metabolic pathways, thus offer new possibilities for therapeutic interventions. The purpose of this review was to summarize the most recent knowledge of the major metabolic changes that occur during fibroblast transition from quiescent to activated states and the evidence linking alterations in fibroblast metabolism to the pathobiology of several common fibrotic diseases and tumor-related diseases. Key Messages: Metabolic disorders are associated with the progression of chronic kidney diseases. Interfering with fibroblast metabolism may be a promising therapeutic strategy for renal fibrosis and other fibrosis-related diseases.
Copyright © 2022 by S. Karger AG, Basel.

Entities:  

Keywords:  Fibroblast activation; Fibroblast proliferation; Metabolic pathways; Renal fibrosis

Year:  2022        PMID: 35527985      PMCID: PMC9021660          DOI: 10.1159/000522417

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  85 in total

Review 1.  From Krebs to clinic: glutamine metabolism to cancer therapy.

Authors:  Brian J Altman; Zachary E Stine; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2016-07-29       Impact factor: 60.716

Review 2.  Control and dysregulation of redox signalling in the gastrointestinal tract.

Authors:  Eric L Campbell; Sean P Colgan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-02       Impact factor: 46.802

3.  Glutaminolysis is required for transforming growth factor-β1-induced myofibroblast differentiation and activation.

Authors:  Karen Bernard; Naomi J Logsdon; Gloria A Benavides; Yan Sanders; Jianhua Zhang; Victor M Darley-Usmar; Victor J Thannickal
Journal:  J Biol Chem       Date:  2017-12-08       Impact factor: 5.157

Review 4.  Systemic sclerosis sine scleroderma.

Authors:  Eugeniusz J Kucharz; Magdalena Kopeć-Mędrek
Journal:  Adv Clin Exp Med       Date:  2017-08       Impact factor: 1.727

Review 5.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

6.  Fibrotic extracellular matrix activates a profibrotic positive feedback loop.

Authors:  Matthew W Parker; Daniel Rossi; Mark Peterson; Karen Smith; Kristina Sikström; Eric S White; John E Connett; Craig A Henke; Ola Larsson; Peter B Bitterman
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

7.  Fibroblast mTOR/PPARγ/HGF axis protects against tubular cell death and acute kidney injury.

Authors:  Yuan Gui; Qingmiao Lu; Mengru Gu; Mingjie Wang; Yan Liang; Xingwen Zhu; Xian Xue; Xiaoli Sun; Weichun He; Junwei Yang; Allan Zijian Zhao; Bo Xiao; Chunsun Dai
Journal:  Cell Death Differ       Date:  2019-04-25       Impact factor: 15.828

8.  Arginine is a key player in fibroblasts during the course of IPF development.

Authors:  Yi Wang; Jianping Zhao; Huilan Zhang; Cong-Yi Wang
Journal:  Mol Ther       Date:  2021-02-26       Impact factor: 11.454

9.  The Heterogeneity of Breast Cancer Metabolism.

Authors:  Jessica Tan; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.